局部晚期宫颈癌新辅助化疗后Bax蛋白作为治疗有效性的指标

探讨Bax蛋白与宫颈癌新辅助化疗疗效之间的关系，用免疫组化方法检测23例局部晚期宫颈癌组织新辅助化疗前后Bax蛋白的表达。结果化疗后2例为临床完全缓解，17例为临床部分缓解，4例患者对新辅助化疗无反应，总有效率为82．61％。NACT前有反应者和无反应者宫颈癌组织的Bax表达无统计学差异（P〉0．05）。对化疗有反应者NACT后BaxWS值有显著性差异（P〈0．05）；无反应者NACT后BaxWS值无统计学差异（P〉0．05）。不同病理类型和临床分期患者NACT前后Bax变化值无显著性差异（P〉0．05）；不同病理分级患者NACT前后Bax变化值有统计学差异（P〈0．05）。说明Bax与化疗疗效有显著相关性。NACT前后Bax变化值与临床分期和病理类型无关，而与病理分级有显著相关性。Bax有可能作为判断化疗疗效的指标。

Expression of Cell Apoptosis Protein-Bax in Locally Advanced Cervical Carcinoma after Neoadjuvant Chemotherapy as an Indicator of the Efficiency of the Therapy

To study the correlation of the expression of Bax protein before and after neoadjuvant chemotherapy with clinical effect, the expression of Bax protein was evaluated in tumor samples by immunohistochemistry in 23 patients with locally advanced cervical cancer before and after neoadjuvant intraarterial chemotherapy. It is resulted that 19 patients in 23 patients, responded to NACT and 4 did not, overall clinical response was 82.61%. The expression of Bax protein did not differ between responders and non-responders before chemotherapy. After chemotherapy, the expression of Bax was significantly higher for responders than for non-responders. Bax discrepancy before and after NACT was associated with grade of differentiation, but not with the others. It is conclused that neoadjuvant intraarterial chemotherapy increased cell apoptosis in tissues of cervical cancer significantly. Chemosensitivity may be related to Bax protein, which may be reference marker of clinical effect.